abstract |
The present invention relates to the use of sST2 in the manufacture of a kit for use in a method for predicting the prognostic risk of CAP patients. In particular, it relates to predicting risk based on the sST2 level of a patient alone, or in combination with the CURB-65 score, or in combination with the PSI score. The invention can effectively predict the prognosis risk of the CAP patient, thereby being capable of carrying out clinical intervention in advance and further improving the prognosis of the CAP patient. |